COVID-19 positive donor for solid organ transplantation.
SARS-CoV-2
donor
recipient
transplant
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
15
04
2022
revised:
01
06
2022
accepted:
16
06
2022
pubmed:
8
7
2022
medline:
21
9
2022
entrez:
7
7
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic has significantly changed organ donation and transplantation worldwide. Since the beginning of the pandemic, the uncertainty regarding the potential route of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created tremendous pressures on transplantation communities, and international organisations have advised against using organs from deceased donors who have tested positive for SARS-CoV-2. The possibility of SARS-CoV-2 transmission through organ donation has only been reported for lung transplantation; hence, based on current experience, transplantation of non-lung organs from donors with active SARS-CoV-2 infection has been considered possible and safe, at least over short-term follow-up. As the evolving outbreak of SARS-CoV-2 continues, alongside the presence of vaccines and new treatment options, clinicians should consider transplanting organs from deceased donors with active SARS-CoV-2 infection to recipients with limited opportunities for transplantation and those with specific natural or vaccine-induced immunity. This article proffers an expert opinion on the use of organs from deceased donors with resolved or active SARS-CoV-2 infection in the absence of more definitive data and standardised acceptance patterns.
Identifiants
pubmed: 35798131
pii: S0168-8278(22)02919-1
doi: 10.1016/j.jhep.2022.06.021
pmc: PMC9251900
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1198-1204Informations de copyright
Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest PAG has the following conflict of interest: Consulting fees from Merck, Sharp & Dohme, Gilead Sciences, Takeda, Shionogi, Allovir; member of speakers bureau for Merck, Sharp & Dohme, Gilead Sciences, Takeda, Atara; MP has no conflicts of interest to declare. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Am J Transplant. 2021 Aug;21(8):2885-2889
pubmed: 33565705
Transpl Infect Dis. 2021 Oct;23(5):e13727
pubmed: 34612553
Dig Liver Dis. 2021 Oct;53(10):1232-1234
pubmed: 34393073
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668
pubmed: 33077007
Am J Transplant. 2020 Jul;20(7):1795-1799
pubmed: 32368850
Am J Transplant. 2020 Jul;20(7):1780-1784
pubmed: 32243677
Transplant Direct. 2022 Jan 13;8(2):e1286
pubmed: 35047665
Transplantation. 2022 Apr 1;106(4):693-695
pubmed: 35238852
Am J Transplant. 2021 Jul;21(7):2600-2604
pubmed: 33621393
Transpl Infect Dis. 2022 Feb;24(1):e13757
pubmed: 34741572
Am J Transplant. 2020 Jul;20(7):1773-1779
pubmed: 32202064
Transpl Infect Dis. 2022 Feb;24(1):e13761
pubmed: 34797031
Am J Transplant. 2020 Jul;20(7):1787-1794
pubmed: 32400087
Am J Transplant. 2020 Jul;20(7):1826-1836
pubmed: 32323460
Transplantation. 2021 Jul 1;105(7):1405-1422
pubmed: 33724248
Am J Transplant. 2021 Nov;21(11):3743-3749
pubmed: 34254424
Lancet Public Health. 2021 Oct;6(10):e709-e719
pubmed: 34474014
Am J Transplant. 2021 Dec;21(12):3919-3925
pubmed: 34467627
Vaccines (Basel). 2022 Jan 09;10(1):
pubmed: 35062756
Curr Transplant Rep. 2021;8(4):281-292
pubmed: 34722116
Wellcome Open Res. 2020 Jul 29;5:181
pubmed: 33283055